(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 21.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Ocular Therapeutix's revenue in 2025 is $59,646,000.On average, 5 Wall Street analysts forecast OCUL's revenue for 2025 to be $9,009,037,270, with the lowest OCUL revenue forecast at $8,345,713,169, and the highest OCUL revenue forecast at $10,800,522,101. On average, 5 Wall Street analysts forecast OCUL's revenue for 2026 to be $10,732,341,814, with the lowest OCUL revenue forecast at $9,360,452,487, and the highest OCUL revenue forecast at $13,205,948,114.
In 2027, OCUL is forecast to generate $18,631,059,924 in revenue, with the lowest revenue forecast at $10,418,202,734 and the highest revenue forecast at $25,307,949,058.